Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled trial of tulisokibart in moderately to severely active Crohn's disease
MOH_2024-05-20_013424Phase 3Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tulisokibart in Crohn's disease (7 arms), sponsored by Merck & Co. Planned start May 2024; status: not yet recruiting.
02
Drugs
tulisokibart
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on MOH_2024-05-20_013424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-05-20_013424.